<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 17, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05206370</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-CYT-04</org_study_id>
    <nct_id>NCT05206370</nct_id>
  </id_info>
  <brief_title>A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers</brief_title>
  <acronym>ORCA-3</acronym>
  <official_title>A Second Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline in Adult Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achieve Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achieve Life Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This placebo-controlled Phase 3 study is being conducted at sites within the United States to&#xD;
      evaluate 3 mg cytisinicline TID for treatment duration of 42 days/6 weeks as well as&#xD;
      repeating that duration for a total of 84 days/12 weeks treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 20, 2022</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants With Smoking Abstinence During the Last 4 Weeks of 6 Weeks Cytisinicline Treatment Versus Placebo Treatment (Wk 3-6)</measure>
    <time_frame>Week 3-6</time_frame>
    <description>Smoking abstinence as verified by weekly expired carbon monoxide (CO) measurements ≤ 10 parts per million (ppm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants With Smoking Abstinence During the Last 4 Weeks of 12 Weeks Cytisinicline Treatment Versus Placebo Treatment (Wk 9-12)</measure>
    <time_frame>Week 9-12</time_frame>
    <description>Smoking abstinence as verified by weekly expired carbon monoxide (CO) measurements ≤ 10 parts per million (ppm).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Continuous Smoking Abstinence to Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Smoking abstinence as verified by monthly expired CO measurements ≤ 10 ppm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who are Relapse-Free at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Relapse is defined as participant reported resuming smoking or an expired CO measure ≥ 10 ppm.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Placebo + Behavioral Support</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cytisinicline + Placebo + Behavioral Support</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one cytisinicline tablet PO TID plus behavioral support for 6 weeks followed by one placebo tablet PO TID plus behavioral support for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cytisinicline + Behavioral Support</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one cytisinicline tablet PO TID plus behavioral support for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytisinicline</intervention_name>
    <description>film-coated oral tablets containing 3 mg cytisinicline</description>
    <arm_group_label>Cytisinicline + Behavioral Support</arm_group_label>
    <arm_group_label>Cytisinicline + Placebo + Behavioral Support</arm_group_label>
    <other_name>Cytisine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>film-coated oral tablets containing matched placebo</description>
    <arm_group_label>Cytisinicline + Placebo + Behavioral Support</arm_group_label>
    <arm_group_label>Placebo + Behavioral Support</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral support</intervention_name>
    <description>Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.</description>
    <arm_group_label>Cytisinicline + Behavioral Support</arm_group_label>
    <arm_group_label>Cytisinicline + Placebo + Behavioral Support</arm_group_label>
    <arm_group_label>Placebo + Behavioral Support</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects, age ≥ 18 years.&#xD;
&#xD;
          2. Current daily cigarette smokers (averaging at least 10 cigarettes per day upon&#xD;
             completing a 7-day screening smoking diary) and who intend to quit smoking.&#xD;
&#xD;
          3. Expired air carbon monoxide (CO) ≥ 10 ppm.&#xD;
&#xD;
          4. Failed at least one previous attempt to stop smoking with or without therapeutic&#xD;
             support.&#xD;
&#xD;
          5. Willing to initiate study treatment on the day after randomization and set a quit date&#xD;
             within 5-7 days of starting treatment.&#xD;
&#xD;
          6. Willing to actively participate in the study's smoking cessation behavioral support&#xD;
             provided throughout the study.&#xD;
&#xD;
          7. Able to fully understand all study requirements, willing to participate, and comply&#xD;
             with dosing schedule.&#xD;
&#xD;
          8. Sign the Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. More than 1 study participant in same household during the 12-week treatment period.&#xD;
&#xD;
          2. Previous cytisinicline treatment in a prior clinical study or any other cytisine&#xD;
             usage.&#xD;
&#xD;
          3. Known hypersensitivity to cytisinicline or any of the excipients.&#xD;
&#xD;
          4. Positive urinary drugs of abuse screen, determined within 28 days before the first&#xD;
             dose of cytisinicline.&#xD;
&#xD;
          5. Clinically significant abnormal serum chemistry or hematology values within 28 days of&#xD;
             randomization (ie, requiring treatment or monitoring).&#xD;
&#xD;
          6. Clinically significant abnormalities in 12-lead ECG determined after minimum of 5&#xD;
             minutes in supine position within 28 days of randomization (ie, requiring treatment or&#xD;
             further assessment).&#xD;
&#xD;
          7. Recent history (within 3 months) of acute myocardial infarction, unstable angina,&#xD;
             stroke, cerebrovascular incident, or hospitalization for congestive heart failure.&#xD;
&#xD;
          8. Current uncontrolled hypertension (blood pressure ≥160/100 mmHg).&#xD;
&#xD;
          9. Currently psychotic or having had a psychotic event within 3 months. If any subject&#xD;
             becomes psychotic during the study, they must be removed from treatment and/or&#xD;
             additional study visits.&#xD;
&#xD;
         10. Currently having suicidal ideation or risk for suicide (&quot;Yes&quot; to either question 4 or&#xD;
             question 5 OR &quot;Yes&quot; to any suicidal behavior question on the C-SSRS with clear&#xD;
             suicidal intent or previous attempt).&#xD;
&#xD;
         11. Current symptoms of moderate to severe depression (depression score ≥11on the HADS).&#xD;
&#xD;
         12. Renal impairment defined as a creatinine clearance (CrCl) &lt;60 mL/min (estimated with&#xD;
             the Cockroft-Gault equation).&#xD;
&#xD;
         13. Hepatic impairment defined as alanine aminotransferase (ALT) or aspartate&#xD;
             aminotransferase (AST) &gt;2.0 x the upper limit of normal (ULN).&#xD;
&#xD;
         14. Women who are pregnant or breast-feeding.&#xD;
&#xD;
         15. Male or female subjects of childbearing potential who do not agree to use acceptable&#xD;
             methods of birth control during the study treatment period.&#xD;
&#xD;
         16. Participation in a clinical study with an investigational drug in the 4 weeks prior to&#xD;
             randomization.&#xD;
&#xD;
         17. Treatment with other smoking cessation medications (bupropion, varenicline,&#xD;
             nortriptyline, or any nicotine replacement therapy [NRT]) in the 4 weeks prior to&#xD;
             randomization or planned use of these other smoking cessation medications during the&#xD;
             study.&#xD;
&#xD;
         18. Use within the 2 weeks prior to randomization or planned use during the study of&#xD;
             non-cigarette and/or noncombustible nicotine products (pipe tobacco, cigars, snuff,&#xD;
             smokeless tobacco, hookah, e-cigarettes/vaping) or marijuana smoking or vaping.&#xD;
&#xD;
         19. Any other reason that the investigator views the subject should not participate or&#xD;
             would be unable to fulfill the requirements for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Cain, Vice-President Clinical Research</last_name>
    <role>Study Director</role>
    <affiliation>Achieve Life Sciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accel Research Sites - DeLand Clinical Research Unit</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affinity Health Corp</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediSphere Medical Research Center, LLC</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Medical Institutes LLC; Princeton Medical Institute</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trial Management Associates, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intend Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Toads, Inc</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>January 12, 2022</study_first_submitted>
  <study_first_submitted_qc>January 12, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2022</study_first_posted>
  <last_update_submitted>February 1, 2023</last_update_submitted>
  <last_update_submitted_qc>February 1, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

